A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
A phase 2 trial of JNJ-79635322 in multiple myeloma, run by Janssen Research & Development, LLC, now recruiting.
Overview
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT07266441 by Janssen Research & Development, LLC, with 157 participants planned, started 2026-02-08 and due to reach its primary completion in 2027-06-14. Interventions recorded: JNJ-79635322. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Shares JNJ-79635322, Johnson & Johnson, Multiple myeloma.
- TrialA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Shares JNJ-79635322, Johnson & Johnson, Multiple myeloma.
- TrialA Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relaps
Shares JNJ-79635322, Johnson & Johnson, Multiple myeloma.
- TrialA Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Shares Johnson & Johnson, Multiple myeloma.
- TrialA Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Shares Johnson & Johnson, Multiple myeloma.
- TrialA Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
Shares Johnson & Johnson, Multiple myeloma.
- TrialA Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Shares Johnson & Johnson, Multiple myeloma.
- TrialA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi
Shares Johnson & Johnson, Multiple myeloma.